FDA Approves Fiasp for Treatment of Children With Diabetes

January 10, 2020

The FDA approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a mealtime insulin option for children with diabetes.

The approval was based on data from a phase 3 trial of the drug’s efficacy and safety compared with conventional insulin aspart in 777 children with type 1 diabetes.

The drug is now available for use in children and adults as either multiple daily injections, continuous subcutaneous insulin infusion pumps, and infusion under supervision by a healthcare professional.

View today's stories